Anna Baird Rider
A5062462959- T-cell and Retrovirus Studies
- Lymphoma Diagnosis and Treatment
- Galectins and Cancer Biology
- CAR-T cell therapy research
- interferon and immune responses
- Ubiquitin and proteasome pathways
- RNA regulation and disease
- Immune Response and Inflammation
- RNA Interference and Gene Delivery
- Cytokine Signaling Pathways and Interactions
Massachusetts General Hospital
2024-2025
Newcastle University
2023
Abstract Purpose: Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms. Experimental Design: Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation. Results: Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma (ENKTCL), T-prolymphocytic leukemia (T-PLL),...
Abstract Molecular studies have highlighted recurrent alterations in epigenetic modifier genes, including TET2, DNMT3A, and IDH2, angioimmunoblastic T-cell lymphoma (AITL). However, the direct impact of gene regulatory elements on expression changes leading to lymphomagenesis remains poorly understood. We focus 3D chromatin organization. Hi-C RNA sequencing was performed diagnostic FFPE tumor samples from seventeen patients with AITL. Two CD4+ T cells individual donors one follicular helper...
<p>Supplementary Methods and Figures</p>
<p>Supplementary Methods and Figures</p>
<div>AbstractPurpose:<p>Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms.</p>Experimental Design:<p>Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation.</p>Results:<p>Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma...
<div>AbstractPurpose:<p>Develop a novel therapeutic strategy for patients with subtypes of mature T-cell and NK-cell neoplasms.</p>Experimental Design:<p>Primary specimens, cell lines, patient-derived xenograft models, commercially available, proprietary anti-KLRG1 antibodies were used screening, target, functional validation.</p>Results:<p>Here we demonstrate that surface KLRG1 is highly expressed on tumor cells in subsets extranodal NK/T-cell lymphoma...